Park Jong-Moo, Kang Kyusik, Cho Yong-Jin, Hong Keun-Sik, Lee Kyung Bok, Park Tai Hwan, Lee Soo Joo, Ko Youngchai, Han Moon-Ku, Lee Jun, Cha Jae-Kwan, Kim Dae-Hyun, Kim Dong-Eog, Kim Joon-Tae, Choi Jay Chol, Yu Kyung-Ho, Lee Byung-Chul, Lee Ji Sung, Lee Juneyoung, Gorelick Philip B, Bae Hee-Joon
Departments of Neurology, Eulji, General Hospital, Eulji University, Seoul.
Ilsan Paik Hospital, Inje University College of Medicine, Goyang.
Ann Neurol. 2016 Apr;79(4):560-8. doi: 10.1002/ana.24602. Epub 2016 Feb 19.
OBJECTIVE: The effect of prestroke aspirin use on initial severity, hemorrhagic transformation, and functional outcome of ischemic stroke is uncertain. METHODS: Using a multicenter stroke registry database, patients with acute ischemic stroke of three subtypes (large artery atherosclerosis [LAA], small vessel occlusion [SVO], or cardioembolism [CE]) were identified. NIH stroke scale (NIHSS) and hemorrhagic transformation at presentation and discharge modified Rankin Scale (mRS) were compared between prestroke aspirin users and nonusers. RESULTS: Among the 10,433 patients, 1,914 (18.3%) reported prestroke aspirin use. On crude analysis, initial NIHSS scores of aspirin users were higher than nonusers (mean difference: 0.35; 95% confidence interval [CI]: 0.04-0.66). However, a multivariable analysis with an application of inverse probability of treatment weighting based on a propensity score of prestroke aspirin, having an interaction effect of prestroke aspirin use and stroke subtype in the model, showed less stroke severity for aspirin users in LAA, but not in SVO and CE than for nonusers; mean difference in NIHSS scores in LAA was -0.97 (95% CI: -1.45 to -0.49). With respect to hemorrhagic transformation and mRS, no significant interaction effects were found. Prestroke aspirin use increased the risk of hemorrhagic transformation (adjusted odd ratio: 1.34; 95% CI: 1.05-1.73), but decreased the odds of the higher discharge mRS (0.86; 0.76-0.96). INTERPRETATION: Prestroke aspirin use may reduce initial stroke severity in atherothrombotic stroke and can improve functional outcome at discharge despite an increase of hemorrhagic transformation irrespective of stroke subtype.
目的:卒中前使用阿司匹林对缺血性卒中的初始严重程度、出血性转化及功能结局的影响尚不确定。 方法:利用多中心卒中登记数据库,确定三种亚型(大动脉粥样硬化[LAA]、小血管闭塞[SVO]或心源性栓塞[CE])的急性缺血性卒中患者。比较卒中前使用阿司匹林者和未使用者的美国国立卫生研究院卒中量表(NIHSS)、就诊时及出院时的出血性转化情况以及改良Rankin量表(mRS)。 结果:在10433例患者中,1914例(18.3%)报告在卒中前使用过阿司匹林。粗分析显示,阿司匹林使用者的初始NIHSS评分高于未使用者(平均差值:0.35;95%置信区间[CI]:0.04 - 0.66)。然而,基于卒中前阿司匹林倾向评分应用治疗权重逆概率的多变量分析显示,模型中存在卒中前阿司匹林使用与卒中亚型的交互作用,LAA型卒中中阿司匹林使用者的卒中严重程度低于未使用者,但SVO型和CE型卒中并非如此;LAA型卒中NIHSS评分的平均差值为 -0.97(95% CI:-1.45至 -0.49)。关于出血性转化和mRS,未发现显著的交互作用。卒中前使用阿司匹林增加了出血性转化的风险(调整比值比:1.34;95% CI:1.05 - 1.73),但降低了出院时mRS评分较高的几率(0.86;0.76 - 0.96)。 解读:卒中前使用阿司匹林可能降低动脉粥样硬化性血栓形成性卒中的初始卒中严重程度,且尽管出血性转化增加,但无论卒中亚型如何,均可改善出院时的功能结局。
Neurology. 2015-3-17
J Stroke Cerebrovasc Dis. 2019-8
J Stroke Cerebrovasc Dis. 2016-2
Medicines (Basel). 2025-7-24
Eur Stroke J. 2023-9
Curr Cardiol Rep. 2021-10-1
Cell Mol Neurobiol. 2022-4
Curr Treat Options Cardiovasc Med. 2019-12-9
J Korean Med Sci. 2019-9-23
J Stroke. 2014-9-30
Circ Cardiovasc Qual Outcomes. 2013-9-1
N Engl J Med. 2012-8-30